12 min listen
Interpreting the Latest Clinical Trial Results of New and Emerging Treatments for nAMD
Interpreting the Latest Clinical Trial Results of New and Emerging Treatments for nAMD
ratings:
Length:
20 minutes
Released:
Jul 29, 2020
Format:
Podcast episode
Description
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Peter Kaiser interpret the latest clinical trial data of new and emerging treatments for nAMD. Transcripts: https://tinyurl.com/Ophthalmology3-4 For CME Credit, click here: https://tinyurl.com/Ophthalmology3-4a
Released:
Jul 29, 2020
Format:
Podcast episode
Titles in the series (90)
Dosing Strategies in nAMD – Real World Applications: Dosing Strategies in nAMD – Real World Applications by MedEdTalks - Ophthalmology